• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to compounds of formula (I), methods for their preparation and their use as selective ligands that bind to adenosine A1 receptors. [Formula I]
    公开号:KR20040064736A
    申请号:KR10-2004-7008956
    申请日:2002-11-28
    公开日:2004-07-19
    发明作者:울리히 로젠트레터；토마스 크래머；미쯔유끼 시마다；발터 휩쉬；니콜레 디드리흐스；토마스 크란；케르스틴 헤닝거；요한네스-페터 스타쉬；랄프 비쉬나트
    申请人:바이엘 헬스케어 아게；
    IPC主号:
    专利说明:

    Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine and uses thereof {SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THE USE OF THE SAME}
    [1] The present invention relates to substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine, a process for its preparation, and its use as a medicament.
    [2] Adenosine, which is a nucleoside constituting adenine and D-ribose, is a cell, particularly with limited oxygen and substance supply, under cell-damaging conditions, eg, in the case of ischemia in various organs (eg heart and brain), -An endogenous factor with protective activity.
    [3] Adenosine is formed intracellularly as an intermediate during the degradation of adenosine-5'-monophosphate (AMP) and S-adenosyl homocysteine, but can be released from the cell, in which case a hormone-like substance by binding to a specific receptor Or acts as a neurotransmitter.
    [4] Under normal oxygen partial pressure conditions, the concentration of free adenosine in the extracellular space is very low. However, under ischemic or hypoxic conditions, extracellular adenosine concentrations of the onset organs increase markedly. Thus, for example, it is known that adenosine inhibits platelet aggregation and increases blood supply to the coronary arteries. It also acts on heart rate, neurotransmitter release and lymphocyte differentiation.
    [5] The purpose of this action of adenosine is to increase the oxygen supply of the affected organ and / or reduce the metabolism of the organ in order to adapt the organ metabolism to the organ blood supply under ischemic or hypoxic conditions.
    [6] The action of adenosine is mediated through specific receptors. To date, subtypes A1, A2a, A2b and A3 are known. The action of these adenosine receptors is mediated intracellularly by messenger cAMP. When adenosine binds to A2a or A2b receptors, intracellular cAMP is increased through activation of membrane-bound adenylate cyclase, and when adenosine binds to A1 or A3 receptors, cells are inhibited through inhibition of adenylate cyclase. My cAMP concentration is reduced.
    [7] According to the present invention, an "adenosine-receptor-selective ligand" is a substance that selectively binds to one or more subtypes of adenosine receptors to mimic (adenosine agonists) or block its actions (adenosine antagonists).
    [8] In the context of the present invention, first, they clearly act on one or more adenosine receptor subtypes, and second, if the activity that can be observed in one or more other adenosine receptor subtypes is relatively weak (coefficient 10 or less), even if present, adenosine receptor ligands. Is considered to be "selective", where with respect to the test method for the selectivity of action, reference is made to the test method described in section A.II.
    [9] Depending on their receptor selectivity, adenosine receptor selective ligands are divided into different classes, for example ligands that selectively bind to A1 or A2 receptors of adenosine, and in the latter case also A2a or A2b receptors, for example of adenosine It can be divided into ligands that selectively bind to. Also possible are adenosine receptor ligands that selectively bind to many of the subtypes of adenosine receptors, for example ligands that selectively bind to the A1 and A2 receptors of adenosine but do not bind to the A3 receptor.
    [10] Such receptor selectivity can be measured by the effect of a substance on a cell line that is stably transfected with the corresponding cDNA and then expresses that receptor subtype (see, eg, ME Olah, H., incorporated herein in its entirety). Ren, J. Ostrowski, KA Jacobson, GL Stiles, "Cloning, expression, and characterization of the unique bovine A1 adenosine receptor.Study on the ligand binding site by site-directed mutagenesis." In J. Biol. Chem. 267 (1992 pages 10764-10770).
    [11] The influence of the substance on the cell line can be monitored by biochemical measurements of intracellular messenger cAMP (KN Klotz, J. Hessling, J. Hegler, C. Owman, B. Kull, BB Fredholm, MJ Lohse, "Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells" in Naunyn Schmiedebergs Arch. Pharmacol. 357 (1998) pages 1-9].
    [12] In the case of the A1 agonist (preferably coupling through the G i protein), a decrease in intracellular cAMP concentration is observed (preferably after direct prior stimulation of adenylate cyclase by forskolin), A1 In the case of antagonists, an increase in intracellular cAMP concentration is observed (preferably after direct prestimulation of adenylate cyclase by forskolin in addition to prestimulation of adenosine or adenosine-like substances). Correspondingly, A2a and A2b agonists (preferably coupling through G s protein) increase cAMP concentrations in cells, and A2a and A2b antagonists decrease cAMP concentrations in cells. In the case of the A2 receptor, direct prior stimulation of adenylate cyclase by forskolin is not useful.
    [13] "Adenosine-receptor-selective" ligands known from the prior art are derivatives based primarily on natural adenosine (S.-A. Poulsen and RJ Quinn, "Adenosine receptors: new opportunities for future drugs" in Bioorganic and Medicinal Chemistry 6 (1998 ) pages 619 to 641). However, most adenosine ligands known from the prior art have the disadvantage that their action is not really receptor specific and their activity is lower than that of natural adenosine or that they have only very weak activity after oral administration. Therefore, they are mainly used for experimental purposes only.
    [14] Further, WO 00/125210 discloses 2-thio-3,5-dicyano-4-aryl-6-aminopyridine of a structure similar to that of the compounds of the present invention. However, the pharmacokinetic properties of the compounds described in that application have little advantage; In particular, they have poor bioavailability after oral administration.
    [15] With the present application, it is an object of the present invention to identify or provide compounds that do not have the disadvantages of the prior art and / or have improved bioavailability.
    [16] The present invention therefore relates to compounds of formula (I) and salts, hydrates, hydrates and solvates thereof.
    [17]
    [18] In the above formula,
    [19] n represents the number 2, 3, or 4,
    [20] R 1 represents hydrogen or (C 1 -C 4 ) -alkyl,
    [21] R 2 represents pyridyl or thiazolyl, some of which are (C 1 -C 4 ) -alkyl, halogen, amino, dimethylamino, acetylamino, guanidino, pyridylamino, thienyl, furyl, imida Zolyl, pyridyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, N- (C 1 -C 4 ) -alkylpiperazinyl, pyrrolidinyl, oxazolyl, isoxazolyl, pyrimidy Unsubstituted up to three times by aryl, pyrazinyl, optionally (C 1 -C 4 ) -alkyl-substituted thiazolyl, or halogen, (C 1 -C 4 ) -alkyl or (C 1 -C 4 ) -alkoxy It may be substituted by phenyl.
    [22] Depending on the type of substitution, the compounds of formula (I) may exist in stereoisomeric forms which are in phase and enantiomers (enantiomers) or inhomogeneous and non-enantiomers (diastereomers). The present invention relates to both enantiomers and diastereomers and to individual mixtures thereof. Like diastereomers, racemic forms can be separated into stereoisomerically homogenous components by known methods. Likewise, the present invention also relates to other tautomers and their salts of the compounds of formula (I).
    [23] Salts of the compounds of formula (I) may be physiologically acceptable salts of the compounds according to the invention with inorganic acids, carboxylic acids or sulfonic acids. Particularly preferred salts are, for example, hydrochloride, hydrobromide, sulfate, phosphate, methanesulfonate, ethanesulfonate, toluenesulfonate, benzenesulfonate, naphthalenedisulfonate, trifluoroacetate, acetate, propionate , Lactate, tartarate, citrate, fumarate, maleate or benzoate.
    [24] Salts which may be mentioned are conventional bases such as alkali metal salts (eg sodium salts or potassium salts), alkaline earth metal salts (eg calcium salts or magnesium salts), or ammonia or organic amines such as eg Ammonium salts derived from, for example, diethylamine, triethylamine, ethyldiisopropylamine, procaine, dibenzylamine, N-methylmorpholine, dihydroabiethylamine, 1-ephenamine or methylpiperidine .
    [25] According to the invention, hydrates and solvates are in the form of compounds of formula (I) which are formed in the solid or liquid phase, by hydration with water, or by coordination with solvent molecules, molecular compounds or complexes. Examples of hydrates are 1.5 hydrates, monohydrates, dihydrates or trihydrates. Likewise suitable are also hydrates or solvates of the salts of the compounds according to the invention.
    [26] In addition, the present invention also encompasses prodrugs of the compounds according to the invention. According to the invention, prodrugs may be biologically active or inactive with respect to a portion thereof, but may be converted into the corresponding biologically active form under physiological conditions (eg metabolically or solvolytically). In the form of compounds of I.
    [27] In the context of the present invention, substituents, unless defined otherwise, have the following meanings:
    [28] Halogen generally represents fluorine, chlorine, bromine or iodine. Preference is given to fluorine, chlorine or bromine. Most preferred is fluorine or chlorine.
    [29] (C 1 -C 4 ) -alkyl denotes a straight or branched chain alkyl radical having 1 to 4 carbon atoms. Examples that may be mentioned are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl.
    [30] (C 1 -C 4 ) -alkoxy refers to a straight or branched chain alkoxy radical having 1 to 4 carbon atoms. Examples that may be mentioned are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, and tert-butoxy.
    [31] n represents the number 2,
    [32] R 1 represents hydrogen, methyl or ethyl,
    [33] R 2 represents pyridyl or thiazolyl, some of which are methyl, ethyl, fluorine, chlorine, amino, dimethylamino, acetylamino, guanidino, 2-pyridylamino, 4-pyridylamino, thienyl, Compounds of formula (I) and salts, hydrates thereof, which may be substituted by pyridyl, morpholinyl, piperidinyl, optionally methyl-substituted thiazolyl, or chlorine, or phenyl optionally substituted up to three times with methoxy Preference is given to hydrates and solvates of salts.
    [34] Also,
    [35] n represents the number 2,
    [36] R 1 represents hydrogen or methyl,
    [37] R 2 represents pyridyl or thiazolyl, some of which are methyl, chlorine, amino, dimethylamino, acetylamino, guanidino, 2-pyridylamino, 4-pyridylamino, thienyl, pyridyl, mor Compounds of formula (I) and salts, hydrates, hydrates of salts thereof, which may be substituted by polyyl, 2-methylthiazol-5-yl, phenyl, 4-chlorophenyl or 3,4,5-trimethoxyphenyl Solvates are particularly preferred.
    [38] Very particular preference is given to compounds from Example 6 of the following structural formula and salts, hydrates, hydrates of salts, solvates thereof.
    [39]
    [40] The invention also provides a process for the preparation of compounds of formula (I), characterized in that the compounds of formula (II) are optionally reacted with compounds of formula (III) in the presence of a base.
    [41]
    [42]
    [43] In the above formula,
    [44] n and R 1 are as defined above,
    [45] R 2 is as defined above,
    [46] X represents a suitable leaving group, as a preferred example halogen, in particular chlorine, bromine, or iodine, or mesylate, tosylate, triflate or 1-imidazolyl.
    [47] The above method can be illustrated by way of example in the following scheme:
    [48]
    [49] Suitable solvents for the process according to the invention are all organic solvents which are inert under the reaction conditions. They are alcohols such as methanol, ethanol and isopropanol, ketones such as acetone and methyl ethyl ketone, acyclic and cyclic ethers such as diethyl ether and tetrahydrofuran, esters such as ethyl acetate or butyl acetate, hydrocarbons such as benzene, xylene , Toluene, hexane or cyclohexane, hydrocarbon chlorides such as dichloromethane, chlorobenzene or dichloroethane, or other solvents such as dimethylformamide, acetonitrile, pyridine or dimethyl sulfoxide (DMSO). Water is also a suitable solvent. Dimethylformamide is preferred. It is also possible to use mixtures of the abovementioned solvents.
    [50] Suitable bases are conventional inorganic or organic bases. They are preferably alkali metal hydroxides such as for example sodium hydroxide or potassium hydroxide, or alkali metal carbonates such as sodium carbonate or potassium carbonate, or alkali metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, or alkali metal alkoxide salts such as methoxy Sodium citrate or potassium methoxylated, sodium ethoxylated or potassium ethoxylated, or tert-butoxylated, or amides such as sodium amidated, bis (trimethylsilyl) lithiated or lithium diisopropylamided, or organometallic compounds Such as butyllithium or phenyllithium, or 1,8-diazabicyclo [5,4,0] undec-7-ene (DBU) or 1,5-diazabicyclo [4,3,0] non-5- Ene (DBN), or other amines such as triethylamine and pyridine. Alkali metal carbonates and alkali metal bicarbonates are preferred.
    [51] The base can be used herein in amounts of 1 to 10 mol, preferably 1 to 5 mol, in particular 1 to 4 mol, based on 1 mol of the compound of formula II.
    [52] The reaction is generally carried out in the temperature range of -78 ° C to + 140 ° C, preferably in the range of -78 to + 40 ° C, in particular at room temperature.
    [53] The reaction can be carried out at atmospheric pressure, pressurized or reduced pressure (eg within the range of 0.5 to 5 bar). In general, the reaction is carried out at atmospheric pressure.
    [54] Compounds of formula (II) are known per se to the person skilled in the art or can be prepared by conventional methods known in the literature, for example by reacting the corresponding benzaldehydes with cyanothioacetamides. In particular, reference may be made to the following references, the contents of which are incorporated herein by reference:
    [55] Dyachenko et al., Russian Journal of Chemistry, Vol. 33, No. 7, 1997, pages 1014 to 1017 and Vol. 34, No. 4, 1998, pages 557 to 563;
    [56] Dyachenko et al., Chemistry of Heterocyclic Compounds, Vol. 34, No. 2, 1998, pages 188 to 194;
    [57] Qintela et al., European Journal of Medicinal Chemistry, Vol. 33, 1998, pages 887 to 897;
    [58] Kandeel et al., Zeitschrift fuer Naturforschung 42b, 107 to 111 (1987).
    [59] Thus, for example, it is also possible to produce compounds of formula (II) from compounds of formula (VI) by reaction with alkali metal sulfides. This preparation method can be exemplarily shown in the following scheme.
    [60]
    [61] The alkali metal sulfides used are preferably sodium sulfides in an amount of 1 to 10 mol, preferably 1 to 5 mol, in particular 1 to 4 mol, based on 1 mol of the compound of formula IV.
    [62] Suitable solvents are all organic solvents which are inert under the reaction conditions. These include N, N-dimethylformamide, N-methylpyrrolidinone, pyridine and acetonitrile. N, N-dimethylformamide is preferred. Mixtures of the abovementioned solvents may also be used.
    [63] The reaction is generally carried out in the temperature range of + 20 ° C to + 140 ° C, preferably in the range of + 20 ° C to + 120 ° C, in particular in the range of + 60 ° C to + 100 ° C.
    [64] The reaction can be carried out at atmospheric pressure, pressurized or reduced pressure (eg within the range of 0.5 to 5 bar). In general, the reaction is carried out at atmospheric pressure.
    [65] Compounds of formula III are either commercially available, known to those skilled in the art, or can be prepared by conventional methods.
    [66] Compounds of formula (IV) are commercially available or known to those skilled in the art, or may be prepared by conventional methods. In particular, reference may be made to the following references, the contents of which are incorporated herein by reference:
    [67] Kambe et al., Synthesis, 531 to 533 (1981);
    [68] Elnagdi et al., Z. Naturforsch. 47b, 572 to 578 (1991).
    [69] The pharmaceutical activity of the compounds of formula (I) can be explained by their action as selective ligands for adenosine A1 receptors. Here, they act as A1 agonists.
    [70] Surprisingly, the compounds of formula (I) have an unexpectedly useful range of pharmacological activity and are therefore particularly suitable for the prevention and / or treatment of diseases.
    [71] In comparison with the prior art, the compounds of formula (I) according to the invention have improved pharmacokinetic properties, in particular better bioavailability after oral administration.
    [72] Compounds of formula (I), alone or in combination with one or more other active compounds, are suitable for the prevention and / or treatment of various diseases, in particular cardiovascular diseases (cardiovascular diseases). Active ingredients suitable for combination are especially active ingredients for the treatment of coronary heart disease, such as, in particular, nitrates, beta blockers, calcium antagonists or diuretics.
    [73] In the context of the present invention, cardiovascular diseases include, for example, the following diseases: coronary artery stenosis, such as restenosis after ballooning of, for example, peripheral vessels, tachycardia, arrhythmia; It is understood to mean peripheral vascular and cardiovascular disease, stable and unstable angina, atrial and ventricular fibrillation.
    [74] The compounds of formula (I) are also particularly suitable for further reducing the size of the myocardial site affected by, for example, infarction.
    [75] The compounds of formula (I) are furthermore also particularly suitable for the treatment and prevention of, for example, thromboembolic diseases and ischemia such as myocardial infarction, stroke and transient ischemic attacks.
    [76] Additional sites of symptoms in which the compounds of formula (I) are particularly suitable are particularly suitable for the prevention and / or treatment of, for example, diseases of the genitourinary site, such as, for example, overactive bladder, erectile dysfunction and female sexual dysfunction, Prevention and / or treatment of inflammatory diseases such as, for example, asthma and inflammatory skin diseases, neuroinflammatory diseases of the central nervous system such as, for example, symptoms after cerebral infarction, Alzheimer's disease, neurodegenerative diseases, and also neurodegenerative diseases As well as being particularly suitable for the prevention and / or treatment of pain and cancer.
    [77] Further specific areas of symptoms are, for example, the prevention and / or treatment of respiratory diseases such as asthma, chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis (mucoadhesion) and pulmonary hypertension.
    [78] Finally, the compounds of formula I are also suitable for the prevention and / or treatment of diabetes, in particular diabetes mellitus, for example.
    [79] The present invention therefore also relates to the use of a compound of formula (I) in the manufacture of a medicament for the aforementioned clinical prophylaxis and / or treatment.
    [80] The invention also relates to the aforementioned clinically preventive and / or therapeutic methods using the compounds of formula (I).
    [81] The subject matter of the present invention also encompasses medicaments comprising at least one compound of formula (I), preferably together with at least one pharmacologically acceptable adjuvant or carrier and the use thereof for the abovementioned purposes.
    [82] In all conventional dosage forms, namely oral, parenteral, inhalation, nasal, sublingual, intrarectal, topical administration, such as, for example, transplantation or stents, or externally, for example, transdermal, for example, It is suitable for administering a compound of. In the case of parenteral administration, mention may be made especially of intravenous, intramuscular and subcutaneous administration, for example subcutaneous depots. Oral or parenteral administration is preferred. Oral administration is particularly preferred.
    [83] Herein, the active compounds may be administered on their own or in the form of preparations. Formulations suitable for oral administration are especially tablets, capsules, pellets, tablets of sugar, pills, granules, solid and liquid aerosols, syrups, emulsions, suspensions and solutions. As used herein, the active compound should be present in an amount to achieve a therapeutic effect. In general, the active compound may be present at a concentration of 0.1 to 100% by weight, in particular 0.5 to 90% by weight, preferably 5 to 80% by weight. In particular, the concentration of the active compound should be present from 0.5 to 90% by weight, ie the active compound should be present in an amount sufficient to achieve the stated dosage range.
    [84] Finally, the active compounds can be converted into conventional formulations by methods known per se. This is accomplished using inert, non-toxic pharmaceutically suitable carriers, excipients, solvents, vehicles, emulsifiers and / or dispersants.
    [85] Excipients that may be mentioned are, for example, water, nontoxic organic solvents such as, for example, paraffin, vegetable oils (eg sesame oil), alcohols (eg ethanol, glycerol), glycols (eg, Polyethylene glycols), solid carriers such as natural or synthetic indicator minerals (eg talc or silicates), sugars (eg lactose), emulsifiers, dispersants (eg polyvinylpyrrolidone) and glidants (For example, magnesium sulfate).
    [86] In the case of oral administration, tablets as well as additives such as sodium citrate may be contained together with auxiliaries such as starch, gelatin and the like. Aqueous formulations for oral administration may further be mixed with a flavor enhancer or colorant.
    [87] In general, in the case of parenteral administration, an amount of about 0.1 to about 10000 μg, preferably about 1 to about 1000 μg, in particular about 1 to about 100 μg, per kg of body weight, is advantageous for the administrator to achieve an effective result. It turned out. For oral administration the amount is about 0.05 to about 5 mg, preferably about 0.1 to about 5 mg, especially about 0.1 to about 1 mg per kg of body weight.
    [88] Nevertheless, it may be necessary to deviate from the stated amounts depending on body weight, route of administration, individual response to the active compound, the type of agent and the time or interval of administration.
    [89] The invention is illustrated by the following non-limiting preferred examples, but are not intended to limit the invention in any way.
    [90] In the examples which follow, percentages are in each case based on weight, unless otherwise indicated; Parts are parts by weight.
    [91] A. Evaluation of Physiological Activity
    [92] I. Detection of Cardiovascular Effects
    [93] After opening the anesthetized rat's chest, the heart was quickly detached and placed in a conventional Langendorf apparatus. The coronary artery was perfused at a constant volume (10 ml / min) and the generated perfusion pressure was recorded via an appropriate pressure sensor. In this setting, the decrease in perfusion pressure corresponds to relaxation of the coronary artery. At the same time, the pressure generated in the heart during each contraction was measured via a balloon introduced into the left ventricle and an additional pressure sensor. The heart rate of the isolated heart was calculated from the number of contractions per hour.
    [94] In this experimental setup, the following values were obtained for the rate of decrease of heart rate (the percentages shown are related to the rate of decrease of heart rate at each concentration):
    [95] Example Compound% Reduction in heart rate at the following concentrations 10 -7 g / ml10 -6 g / ml One15.0%17.5% 615.5%20.0%
    [96] II. Determination of Adenosine A1, A2a, A2b and A3 Functionality
    [97] a) Determination of indirect adenosine functionality by gene expression
    [98] Cells of CHO (Chinese hamster ovary) permanent cell lines were stably transfected with cDNA for adenosine receptor subtypes A1, A2a, and A2b. Adenosine A1 receptors were coupled with adenylate cyclase by Gi proteins, while adenosine A2a and A2b receptors were coupled by Gs proteins. Correspondingly, the formation of cAMP in the cells was inhibited or stimulated, respectively. Thereafter, the expression of luciferase is regulated by the cAMP-dependent promoter. The luciferase test is carried out with several test parameters such as cell density, growth duration and test incubation, forskolin concentration and medium composition for the purpose of high sensitivity and high reproducibility, low parameters and good suitability for performance in robotic systems. Optimized by changing. The following test protocol was used for pharmacological characterization of cells and robot aid material screening.
    [99] Preserved cultures were incubated at 37 ° C. under 5% CO 2 , in DMEM / F12 medium containing 10% FCS (foetal calf serum), divided by 1:10 in each case after 2-3 days. Test cultures were seeded in 384-well plates at a rate of 1000 to 3000 cells per well and incubated at 37 ° C. for about 48 hours. The medium was then replaced with physiological sodium chloride solution (130 mM sodium chloride, 5 mM potassium chloride, 2 mM calcium chloride, 20 mM HEPES, 1 mM magnesium chloride 6H 2 O, 5 mM NaHCO 3 , pH 7.4). The material dissolved in DMSO was diluted three times (1:10) with physiological sodium chloride and pipetted into the test culture (maximum final concentration of DMSO in the test mixture: 0.5%). In this method, final material concentrations of, for example, 5 μM to 5 nM were obtained. After 10 minutes, forskolin was added to A1 cells, then all cultures were incubated at 37 ° C. for 4 hours. Thereafter, 35 μl and 50% luciferase substrate with 50% solubilizer (30 mM disodium hydrogen phosphate, 10% glycerol, 3% TritonX100, 25 mM TrisHCl, 2 mM dithiothreitol (DTT), pH 7.8) Solution (2.5 mM ATP, 0.5 mM Luciferin, 0.1 mM Coenzyme A, 10 mM Trisine, 1.35 mM Magnesium Sulfate, 15 mM DTT, pH 7.8) is added to the test culture and the plate is shaken for about 1 minute and luciferase Activity was measured using a camera system. In this experiment, adenosine-like compound NECA (5-N-ethylcarboxamido-adenosine), which binds to all adenosine receptor subtypes with high affinity and has an agonist effect, was used as the standard compound (Klotz, KN, Hessling, J., Hegler, J., Owman, C., Kull, B., Fredholm, BB, Lohse, MJ, Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells, Naunyn Schmiedebergs Arch Pharmacol, 357 (1998), 1-9].
    [100] Table 1 below shows the values obtained for the stimulation of the adenosine receptor subtypes by the compounds from Examples 1 and 6 at different concentrations.
    [101] Stimulation of Adenosine Receptors by Compounds from Examples 1 and 6 at Different Concentrations Receptor subtypeExample 1Example 6 10 nmol1 nmol0.3 nmol10 nmol1 nmol0.3 nmol A14%11%56%7%25%45% A2a-2%2%-One%2%4%0% A2b8%6%2%29%3%0
    [102] The table shows the% values of the corresponding standard stimuli. The measured value for A2a and A2b receptors is the percentage value of maximum stimulation achieved by NECA; The measured value for the A1 receptor is the percentage value (corresponding to 100% value) following direct prior stimulation of adenylate cyclase with 1 μmol forskolin. Thus, A1 agonists exhibit a decrease in the activity of luciferase (value measured at less than 100%).
    [103] b) Determination of direct adenosine functionality by the method of detecting cAMP
    [104] Cells of permanent cell lines of CHO (Chinese hamster ovary) were stably transfected with cDNA for adenosine receptor subtypes A1, A2a, A2b and A3. Binding of this material to the A2a or A2b receptor subtypes was determined by measuring intracellular cAMP concentrations in these cells using conventional radioimmunoassay (cAMP RIA, IBL GmbH, Hamburg, Germany).
    [105] When the substance acts as an agent, the binding of the substance is expressed as an increase in intracellular cAMP concentration. In these experiments, adenosine-like compound NECA (5-N-ethylcarboxamido-adenosine) with high affinity but non-selective binding to all adenosine receptor subtypes and having an agonistic effect was used as reference compound ( Klotz, KN, Hessling, J., Hegler, J., Owman, C., Kull, B., Fredholm, BB, Lohse, MJ, Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells, Naunyn Schmiedebergs Arch Pharmacol, 357 (1998), 1-9]).
    [106] Adenosine receptors A1 and A3 were coupled to Gi proteins, ie stimulation of these receptors inhibited adenylate cyclase, resulting in decreased intracellular cAMP levels. To identify A1 / A3 receptor agonists, adenylate cyclase was stimulated with forskolin. However, further stimulation of the A1 / A3 receptors inhibited adenylate cyclase, which means that A1 / A3 receptor agonists can be detected by a relatively low content of cAMP in cells.
    [107] In order to detect antagonist effects on adenosine receptors, recombinant cells transfected with the corresponding receptors were pre-stimulated with NECA and the effect of this material on the reduction of intracellular cAMP concentration by this pre-stimulation was studied. In these experiments, XAC (xanthine amine equivalents) with high affinity binding to all adenosine receptor subtypes and having an antagonist effect were used as reference compounds (Mueller, CE, Stein, B., Adenosine receptor antagonists: structures and potential therapeutic applications, Current Pharmaceutical Design, 2 (1996) 501-530].
    [108] III. Pharmacokinetic Studies
    [109] Pharmacokinetic data were determined after intravenous and oral administration of various materials to mice, rats, and dogs as solutions. In this regard, blood samples were collected up to 24 hours after administration. The concentration of unmodified material was determined by bioanalytical method (HPLC or HPLC-MS) in plasma samples obtained from blood samples. The pharmacokinetic parameters were subsequently investigated from the plasma concentration time course obtained with this method. Table 2 below shows the bioavailability in different species.
    [110] Bioavailability after Oral AdministrationmouseRatdog Example 22 of WO 00/125210Not measurable * (3 mg / kg orally)Not measurable * (10 mg / kg orally)1.47% (1 mg / kg orally) Compound from Example 131.5% (1 mg / kg orally)5.0% (3 mg / kg orally)32.6% (3 mg / kg orally) Compound from Example 641.3% (3 mg / kg orally)42.3% (3 mg / kg orally)28.5% (1 mg / kg orally) * Plasma levels at all measurement time points were below the measurement limit (<1 μg / L).
    [111] B. Process Examples
    [112] Abbreviations used:
    [113] DBU 1,8-diazabicyclo [5,4,0] undec-7-ene
    [114] DMF Dimethylformamide
    [115] ESI Electrospray Ionization (for MS)
    [116] HEPES 2- [4- (2-hydroxyethyl) piperazino] ethanesulfonic acid
    [117] HPLC high pressure, high performance, liquid chromatography
    [118] b.p. Boiling Point
    [119] MS mass spectroscopy
    [120] p.a. Analytical
    [121] RT room temperature
    [122] Tris 2-amino-2- (hydroxymethyl) -1,3-propanediol
    [123] Manufacturing Example
    [124] Example 1
    [125] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-[(3-pyridinylmethyl) sulfanyl] pyridine-3,5-dicarbonitrile
    [126] Step 1:
    [127] 4- (2-methoxyethoxy) benzaldehyde
    [128]
    [129] 146.5 g (1.2 mol) of 4-hydroxybenzaldehyde is dissolved in DMF, 20 g (0.12 mol) of potassium iodide, 134.6 g (1.2 mol) of potassium tert-butoxide and 170.2 g (1.8 mol) of 2-chloroethyl methyl ether Was added. The reaction mixture was stirred at 80 ° C for 16 h. For workup, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in 1 L of ethyl acetate and extracted with 0.5 L of 1N aqueous sodium hydroxide solution. The ethyl acetate phase was dried over magnesium sulfate and concentrated under reduced pressure. The residue obtained after concentration was distilled under high vacuum (b.p. = 100 ° C. at 0.45 mbar). This gave 184.2 g (85% of theory) of the product.
    [130] MS (ESIpos): m / z = 181 (M + H) +
    [131] 1 H-NMR (300 MHz, CDCl 3 ): δ = 3.5 (s, 3H); 3.8 (tr, 2 H); 4.2 (tr, 2 H); 7.0 (d, 2 H); 7.8 (d, 1 H); 9.9 (s, 1 H).
    [132] Step 2:
    [133] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile
    [134]
    [135] 18 g (100 mmol) of 4- (2-methoxyethoxy) benzaldehyde in 100 ml of ethanol, 10 g (200 mmol) of cyanothioacetamide and 20.2 g (200 mmol) of N-methylmorpholine were refluxed for 3 hours. Heated. After cooling, the precipitated crystals were suction filtered, washed with a small amount of ethanol and dried under reduced pressure. This gave 12 g (31% of theory) of product containing 0.5 mol equivalent of N-methylmorpholine.
    [136] MS (ESIpos): m / z = 327 (M + H) +
    [137] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 2.8 (tr, 4H, N-methylmorpholine signal); 3.3 (s, 3 H); 3.7 (m, 2H + 4H N-methylmorpholine signal); 4.2 (tr, 2 H); 7.1 (d, 2 H); 7.4 (d, 2 H); 7.6 (s, broad, 2 H).
    [138] Step 3:
    [139] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-[(3-pyridinylmethyl) sulfanyl] pyridine-3,5-dicarbonitrile
    [140]
    [141] 4.28 g (11.36 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile; starting material was 0.5 mol equivalent of N-methylmorpholine Therefore, the purity is 86.6%). It was dissolved in 40 ml. Then 3.34 g (39.75 mmol) of sodium bicarbonate and 2.48 g (15.1 mmol) of 3-picolyl chloride hydrochloride were added. The suspension was stirred overnight at RT, 40 ml of ethanol were added and the mixture was then heated at about 40 ° C. 19 ml of water were then added dropwise. The precipitate was suction filtered and dried under reduced pressure. This gave 3.70 g (78% of theory) of the product.
    [142] MS (ESIpos): m / z = 418 (M + H) +
    [143] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 3.3 (s, 3H); 3.7 (tr, 2 H); 4.2 (tr, 2 H); 4.5 (s, 2 H); 7.1 (d, 2 H); 7.35 (dd, 1 H); 7.45 (d, 2 H); 7.9 (d tr, 1 H); 8.1 (s, broad, 2 H); 8.45 (dd, 1 H); 8.75 (d, 1 H).
    [144] Example 2
    [145] 2-amino-6-[(2-chloro-1,3-thiazol-4-yl) methylsulfanyl]-[4- (2-methoxyethoxy) -phenyl] pyridine-3,5-dicarbo Nitrile
    [146]
    [147] 100 mg (0.31 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 1 ml of DMF. Then 103 mg (1.23 mmol) of sodium bicarbonate and 77.2 mg (0.46 mmol) of 4-chloromethyl-2-chloro-1,3-thiazole were added. The suspension was shaken overnight at RT and water was added. The precipitate was suction filtered, washed with ethanol and diethyl ether and dried at 40 ° C. under reduced pressure. This gave 123 mg (88% of theory) of the product.
    [148] MS (ESIpos): m / z = 458 (M + H) +
    [149] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 3.3 (s, 3H); 3.7 (tr, 2 H); 4.2 (tr, 2 H); 4.5 (s, 2 H); 7.1 (d, 2 H); 7.45 (d, 2 H); 7.8 (s, 1 H); 8.05 (s, broad, 2 H).
    [150] Example 3
    [151] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-[(2-phenyl-1,3-thiazol-4-yl) methylsulfanyl] pyridine-3,5-dica Levonitrile
    [152]
    [153] 100 mg (0.31 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 1 ml of DMF. Then 103 mg (1.23 mmol) of sodium bicarbonate and 96.4 mg (0.46 mmol) of 4-chloromethyl-2-phenyl-1,3-thiazole were added. The suspension was shaken overnight at RT and water was added. The precipitate was suction filtered, washed with ethanol and diethyl ether and dried at 40 ° C. under reduced pressure. This gave 149 mg (97% of theory) of the product.
    [154] MS (ESIpos): m / z = 500 (M + H) +
    [155] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 3.3 (s, 3H); 3.7 (tr, 2 H); 4.2 (tr, 2 H); 4.5 (s, 2 H); 7.1 (d, 2 H); 7.5 (m, 5 H); 7.8 (s, 1 H); 7.9 (m, 2 H); 8.05 (s, broad, 2 H).
    [156] Example 4
    [157] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-[(2- (thiophen-2-yl) -1,3-thiazol-4-yl) -methylsulfanyl ] Pyridine-3,5-dicarbonitrile
    [158]
    [159] 100 mg (0.31 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 1 ml of DMF. Then 103 mg (1.23 mmol) of sodium bicarbonate and 96.4 mg (0.46 mmol) of 4-chloromethyl-2- (thiophen-2-yl) -1,3-thiazole were added. The suspension was shaken overnight at RT and water was added. The precipitate was suction filtered, washed with ethanol and diethyl ether and dried at 40 ° C. under reduced pressure. This gave 146 mg (84% of theory) of product.
    [160] MS (ESIpos): m / z = 506 (M + H) +
    [161] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 3.3 (s, 3H); 3.7 (tr, 2 H); 4.2 (tr, 2 H); 4.6 (s, 2 H); 7.15 (m, 3 H); 7.5 (d, 2 H); 7.65 (d, 1 H); 7.75 (d, 1 H); 7.8 (s, 1 H); 8.1 (s, broad, 2 H).
    [162] Example 5
    [163] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-[(2- (thiophen-3-yl) -1,3-thiazol-4-yl) -methylsulfanyl ] Pyridine-3,5-dicarbonitrile
    [164]
    [165] 100 mg (0.31 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 1 ml of DMF. Then 103 mg (1.23 mmol) of sodium bicarbonate and 96.4 mg (0.46 mmol) of 4-chloromethyl-2- (thiophen-3-yl) -1,3-thiazole were added. The suspension was shaken overnight at RT and water was added. The precipitate was suction filtered, washed with ethanol and diethyl ether and dried at 40 ° C. under reduced pressure. This gave 141 mg (82% of theory) of the product.
    [166] MS (ESIpos): m / z = 506 (M + H) +
    [167] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 3.3 (s, 3H); 3.7 (tr, 2 H); 4.2 (tr, 2 H); 4.6 (s, 2 H); 7.15 (d, 2 H); 7.5 (d, 2 H); 7.55 (d, 1 H); 7.7 (dd, 1 H); 7.8 (s, 1 H); 8.1 (s, broad, 2 H); 8. 15 (d, 1 H).
    [168] Example 6
    [169] 2-amino-6-({[2- (4-chlorophenyl) -1,3-thiazol-4-yl] methyl} sulfanyl) -4- [4- (2-hydroxyethoxy) phenyl] Pyridine-3,5-dicarbonitrile
    [170] Route 1
    [171] First step:
    [172] 2-amino-4- [4- (2-hydroxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile
    [173]
    [174] 12.46 g (75 mmol) of 4- (2-hydroxyethoxy) benzaldehyde, 15.02 g (150 mmol) of cyanothioacetamide and 15.15 g (150 mmol) of N-methylmorpholine were initially dissolved in 75 ml of ethanol and Heated to reflux for 3 hours. After cooling, the reaction solution was concentrated under reduced pressure. The residue was dissolved in 1N aqueous sodium hydroxide solution and washed twice with ethyl acetate. The sodium hydroxide phase was acidified with 1N hydrochloric acid and the precipitated crystals were suction filtered and dried at 45 ° C. under reduced pressure. This gave 12.05 g (51% of theory) of the product.
    [175] MS (ESIpos): m / z = 313 (M + H) + , 330 (M + NH 4 ) +
    [176] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 3.7 (t, 2H); 4.1 (t, 2 H); 7.1 (d, 2 H); 7.4 (d, 2 H); 8.0 (br s, 2 H).
    [177] Second step:
    [178] 2-amino-6-({[2- (4-chlorophenyl) -1,3-thiazol-4-yl] methyl} sulfanyl) -4- [4- (2-hydroxyethoxy) phenyl] Pyridine-3,5-dicarbonitrile
    [179]
    [180] 6.91 g (22.12 mmol) of 2-amino-4- [4- (2-hydroxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 150 ml of DMF. Then 7.44 g (66.35 mmol) of 1,8-diazabicyclo [5,4,0] undec-7-ene and 10.8 g of 4-chloromethyl-2- (4-chlorophenyl) -1,3-thiazole ( 44.24 mmol) was added. The suspension was stirred at rt overnight, 50 g of silica gel was added and the mixture was concentrated under reduced pressure. The material mixture on silica was purified by chromatography on silica (mobile phase: toluene to toluene / ethyl acetate, 1: 1 mixture). This gave 5.5 g (47% of theory) of the product.
    [181] MS (ESIpos): m / z = 521 (M + H) +
    [182] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 3.7 (dt, 2H); 4.1 (t, 2 H); 4.6 (s, 2 H); 4.9 (t, 1 H); 7.1 (d, 2 H); 7.4 (d, 2 H); 7.5 (d, 2 H); 7.9 (m, 3 H); 8.1 (br s, 2 H).
    [183] Route 2:
    [184] Alternatively, the product is also isolated without 2-amino-4- [4- (2-hydroxyethoxy) phenyl] -6-sulfanyl-3,5-pyridinedicarbonitrile, and 2- [4- ( It can be prepared by reacting 2-hydroxyethoxy) -benzylidene] malononitrile with 2-cyanothioacetamide and 4-chloromethyl-2- (4-chlorophenyl) -1,3-thiazole. :
    [185] First step:
    [186] 2- [4- (2-hydroxyethoxy) -benzylidene] malononitrile
    [187]
    [188] 1000 g (5.85 mol) of 4- (2-hydroxyethoxy) benzaldehyde and 425 g (6.43 mol) of malonodinitrile were dissolved in 5000 ml of isopropyl alcohol and 5 g (0.059 mol) of piperidine were added. The mixture was heated at 80 ° C. for 16 hours and then cooled to 3 ° C. to isolate the product. The product was suction filtered and washed with 400 ml of ice cold isopropyl alcohol. Then it was dried under vacuum (40 mbar) at 50 ° C. for 45 hours.
    [189] Yield: 1206 g of pale yellow crystals (94.6% of theory)
    [190] 1 H (400 MHz, CDCl 3 ): 3.95-4.32 m (4H), 6.95-7.15 (m, 2H), 7.61 (s, 1H), 7.85-7.95 (m, 1H).
    [191] Second step:
    [192] 4-chloromethyl-2- (4-chlorophenyl) -1,3-thiazole
    [193]
    [194] 171.65 g (1.0 mol) of 4-chlorothiobenzamide were dissolved in 550 ml of isopropyl alcohol and 133.3 g (1.05 mol) of 1,3-dichloroacetone were added over a period of 3 hours at up to 30 ° C. The mixture was stirred at 40 ° C for 5.5 h and then at 20 ° C for 10 h. To complete the reaction, the mixture was then heated at 55 ° C. for 7.5 h. The product was cooled to 10 ° C. and isolated by adding 950 ml of water. The pH value was adjusted to 4-5 using sodium hydroxide solution and the product was suction filtered.
    [195] Yield: 220.9 g of white or pale yellow crystals (91% of theory)
    [196] 1 H (400 MHz, CDCl 3 ): 4.90 (s, 2H, CH 2 ), 7.5-7.55 (m, 2H), 7.85 (s, 1H, thiazole), 7.9-7.95 (m, 2H)
    [197] Third step:
    [198] 2-amino-6-({[2- (4-chlorophenyl) -1,3-thiazol-4-yl] methyl} sulfanyl) -4- [4- (2-hydroxyethoxy) phenyl] -3,5-pyridinedicarbonitrile
    [199]
    [200] 428.4 g (2.0 mol) 2- [4- (2-hydroxyethoxy) -benzylidene] malononitrile, 108.4 g (1.05 mol) 2-cyanothioacetamide and 4-chloromethyl-2- (4 244.1 g (1.0 mol) of -chlorophenyl) -1,3-thiazole were suspended in 3.4 L of methanol and 556.1 g (3.0 mol) of tributylamine were added over a period of 60 minutes. The mixture was stirred at rt for 20 h, then the product was filtered off. After drying in vacuo, the crude product (360.8 g, crude yield: 70% of theory) was suspended in 3 l of dichloromethane and stirred at 35 ° C. for 2 hours. The product was filtered off and dried under high vacuum. Crystals white at this stage can be further purified by recrystallization from tetrahydrofuran / water (1: 1).
    [201] Yield: 353.5 g of white crystals (68% of theory)
    [202] MS (EI): m / z = 520.00
    [203] Example 7
    [204] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-[(2-pyridinylmethyl) sulfanyl] pyridine-3,5-dicarbonitrile
    [205]
    [206] 100 mg (0.31 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 1 ml of DMF. Then 103 mg (1.23 mmol) of sodium bicarbonate and 75.4 mg (0.46 mmol) of 2-picolyl chloride hydrochloride were added. The suspension was shaken overnight at RT and water was added. The precipitate was suction filtered, washed with ethanol and diethyl ether and dried at 40 ° C. under reduced pressure. This gave 104 mg (81% of theory) of the product.
    [207] MS (ESIpos): m / z = 418 (M + H) +
    [208] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 3.3 (s, 3H); 3.7 (tr, 2 H); 4.2 (tr, 2 H); 4.6 (s, 2 H); 7.1 (d, 2 H); 7.4 (dd, 1 H); 7.45 (d, 2 H); 7.65 (d, 1 H); 7.75 (tr, 1 H); 8.0 (s, broad, 2 H); 8.5 (d, 1 H).
    [209] Example 8
    [210] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-[(2-methyl-1,3-thiazol-4-yl) methylsulfanyl] pyridine-3,5-dica Levonitrile
    [211]
    [212] 100 mg (0.31 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 1 ml of DMF. Then 103 mg (1.23 mmol) of sodium bicarbonate and 90.5 mg (0.61 mmol) of 4-chloromethyl-2-methyl-1,3-thiazole were added. The suspension was shaken overnight at RT and water was added. The precipitate was suction filtered and dried at 40 ° C. under reduced pressure. This gave 88.8 mg (66.2% of theory) of the product.
    [213] MS (ESIpos): m / z = 438 (M + H) +
    [214] Example 9
    [215] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-[(2-amino-1,3-thiazol-4-yl) methylsulfanyl] pyridine-3,5-dica Levonitrile
    [216]
    [217] 100 mg (0.31 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 1 ml of DMF. Then 103 mg (1.23 mmol) of sodium bicarbonate and 68.3 mg (0.46 mmol) of 4-chloromethyl-2-amino-1,3-thiazole were added. The suspension was shaken overnight at RT and water was added. The precipitate was suction filtered, washed with ethanol and diethyl ether and dried at 40 ° C. under reduced pressure. This gave 115.9 mg (86.2% of theory).
    [218] MS (ESIpos): m / z = 439 (M + H) +
    [219] Example 10
    [220] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-[(2- (2-pyridyl) -1,3-thiazol-4-yl) methylsulfanyl] pyridine- 3,5-dicarbonitrile
    [221]
    [222] 50 mg (0.15 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 1 ml of DMF. Then 51.5 mg (0.61 mmol) of sodium bicarbonate and 58.6 mg (0.23 mmol) of 4-chloromethyl-2- (2-pyridyl) -1,3-thiazole were added. The suspension was shaken overnight at RT and water was added. The precipitate was suction filtered, washed with ethanol and diethyl ether and dried at 40 ° C. under reduced pressure. This gave 67.4 mg (87.9% of theory) of the product.
    [223] MS (ESIpos): m / z = 501 (M + H) +
    [224] Example 11
    [225] 2-amino-4- [4- (2-hydroxyethoxy) phenyl] -6-{[(2-methyl-1,3-thiazol-4-yl) methyl] -sulfanyl} pyridine-3, 5-dicarbonitrile
    [226]
    [227] 31.2 mg (0.1 mmol) of 2-amino-4- [4- (2-hydroxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 0.3 ml of DMF. Then 33.6 mg (0.4 mmol) of sodium bicarbonate and 26.7 mg (0.15 mmol) of 4-methyl-2-chloro-1,3-thiazole hydrochloride were added. The suspension was shaken overnight at RT, filtered and preparative HPLC [column: Macherey-Nagel VP 50/21 Nucleosil 100-5 C18 Nautilus, 20 × 50 mm; Flow rate: 25 ml / min; Gradient (A = acetonitrile, B = water + 0.3% trifluoroacetic acid): 0 min 10% A; 2.0 min 10% A; 6.0 min 90% A; 7.0 min 90% A; 7.1 min 10% A; 8.0 min 10% A; Detection: 220 nm]. Concentration of the appropriate fractions gave 20.2 mg (47.7% of theory).
    [228] MS (ESIpos): m / z = 424 (M + H) +
    [229] Example 12
    [230] 2-amino-6-{[(2-amino-1,3-thiazol-4-yl) methyl] sulfanyl} -4- [4- (2-hydroxyethoxy) phenyl] pyridine-3,5 Dicarbonitrile
    [231]
    [232] 31.2 mg (0.1 mmol) of 2-amino-4- [4- (2-hydroxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile were dissolved in 0.3 ml of DMF. Then 33.6 mg (0.4 mmol) of sodium bicarbonate and 22.3 mg (0.15 mmol) of 4-amino-2-chloro-1,3-thiazole were added. The suspension was shaken overnight at RT, filtered and preparative HPLC [column: Macherey-Nagel VP 50/21 Nucleosil 100-5 C18 Nautilus, 20 × 50 mm; Flow rate: 25 ml / min; Gradient (A = acetonitrile, B = water + 0.3% trifluoroacetic acid): 0 min 10% A; 2.0 min 10% A; 6.0 min 90% A; 7.0 min 90% A; 7.1 min 10% A; 8.0 min 10% A; Detection: 220 nm]. Concentration of the appropriate fractions gave 35.7 mg (84.1% of theory).
    [233] MS (ESIpos): m / z = 425 (M + H) +
    [234] Example 13
    [235] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-({[2- (4-morpholinyl) -1,3-thiazol-4-yl] -methyl} sul Panyl) pyridine-3,5-dicarbonitrile
    [236] Step 1:
    [237] 4- [4- (chloromethyl) -1,3-thiazol-2-yl] morpholine
    [238]
    [239] 11.51 g (78.76 mmol) of 4-morpholinecarbothioamide and 10.00 g (78.76 mmol) of dichloroacetone in 100 ml of ethanol were heated to reflux for 1 hour. The colorless solid precipitated from the pink solution was cooled, then suction filtered and washed twice with ethanol. This gave 12.96 g (75% of theory) of the product.
    [240] MS (ESIpos): m / z = 219 (M + H) +
    [241] Step 2:
    [242] 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-({[2- (4-morpholinyl) -1,3-thiazol-4-yl] -methyl} sul Panyl) pyridine-3,5-dicarbonitrile
    [243]
    [244] 2 g (6.13 mmol) of 2-amino-4- [4- (2-methoxyethoxy) phenyl] -6-sulfanylpyridine-3,5-dicarbonitrile and 4- [4- (chloromethyl)- 2.68 g (12.26 mmol) of 1,3-thiazol-2-yl] -morpholine were dissolved in anhydrous DMF (50 ml) and 1.83 ml (12.26 mmol) of DBU were added. After stirring for 3 h at RT, the solvent was removed using a rotary evaporator and the residue was preparative HPLC (column: Kromasil 100 C18 250 x 20 mm, 10 μm; acetonitrile / water gradient: 10% acetonitrile 3 min, then 30 Over a period of minutes, increased to 80% acetonitrile; flow rate: 25 ml / min). This gave 1.70 g (55% of theory) of the product.
    [245] MS (ESIpos): m / z = 509 (M + H) +
    [246] 1 H-NMR (300 MHz, DMSO-d 6 ): δ = 3.3 (m, 7H); 3.7 (m, 6 H); 4.2 (tr, 2 H); 4.4 (s, 2 H); 6.95 (s, 1 H); 7.15 (d, 2 H); 7.45 (d, 2 H); 8.0 (s, broad, 2 H).
    [247] The examples described in Table 3 were prepared similarly to Example 13. Chloromethylthiazole used as starting material can be obtained commercially or prepared analogously to step 1 of Example 13.
    [248]
    [249]
    [250]
    [251]
    [252]
    [253]
    [254]
    权利要求:
    Claims (11)
    [1" claim-type="Currently amended] Compounds of formula I and salts, hydrates, hydrates and solvates thereof.
    [Formula I]
    In the above formula,
    n represents the number 2, 3, or 4,
    R 1 represents hydrogen or (C 1 -C 4 ) -alkyl,
    R 2 represents pyridyl or thiazolyl, some of which are (C 1 -C 4 ) -alkyl, halogen, amino, dimethylamino, acetylamino, guanidino, pyridylamino, thienyl, furyl, imida Zolyl, pyridyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, N- (C 1 -C 4 ) -alkylpiperazinyl, pyrrolidinyl, oxazolyl, isoxazolyl, pyrimidy Unsubstituted up to three times by aryl, pyrazinyl, optionally (C 1 -C 4 ) -alkyl-substituted thiazolyl, or halogen, (C 1 -C 4 ) -alkyl or (C 1 -C 4 ) -alkoxy It may be substituted by phenyl.
    [2" claim-type="Currently amended] The method of claim 1,
    n represents the number 2,
    R 1 represents hydrogen, methyl or ethyl,
    R 2 represents pyridyl or thiazolyl, some of which are methyl, ethyl, fluorine, chlorine, amino, dimethylamino, acetylamino, guanidino, 2-pyridylamino, 4-pyridylamino, thienyl, Compounds of formula (I) and salts, hydrates thereof, which may be substituted by pyridyl, morpholinyl, piperidinyl, optionally methyl-substituted thiazolyl, or phenyl optionally substituted up to three times with chlorine or methoxy, Hydrates and solvates of salts.
    [3" claim-type="Currently amended] The method of claim 1,
    n represents the number 2,
    R 1 represents hydrogen or methyl,
    R 2 represents pyridyl or thiazolyl, some of which are methyl, chlorine, amino, dimethylamino, acetylamino, guanidino, 2-pyridylamino, 4-pyridylamino, thienyl, pyridyl, mor Compounds of formula (I) and salts, hydrates, hydrates of salts thereof, which may be substituted by polyyl, 2-methylthiazol-5-yl, phenyl, 4-chlorophenyl or 3,4,5-trimethoxyphenyl Solvates.
    [4" claim-type="Currently amended] The compound according to any one of claims 1 to 3, and a salt, a hydrate, a hydrate, and a solvate thereof having the following structure.

    [5" claim-type="Currently amended] A process for the preparation of a compound of formula (I) as defined in claim 1 characterized in that the compound of formula (II) is reacted with the compound of formula (III).
    [Formula II]
    [Formula III]
    In the above formula,
    n and R 1 are as defined in claim 1,
    R 2 is as defined in claim 1,
    X represents a leaving group.
    [6" claim-type="Currently amended] A compound of formula (I) as defined in claim 1 for the prevention and / or treatment of a disease.
    [7" claim-type="Currently amended] A medicament comprising at least one compound of formula (I) as defined in claim 1 and at least one adjuvant.
    [8" claim-type="Currently amended] A medicament comprising at least one compound of formula I as defined in claim 1 and at least one further active compound.
    [9" claim-type="Currently amended] Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for the prophylaxis and / or treatment of cardiovascular diseases.
    [10" claim-type="Currently amended] Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for the prophylaxis and / or treatment of diseases and cancers of the genitourinary region.
    [11" claim-type="Currently amended] Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for the prophylaxis and / or treatment of inflammatory and neuroinflammatory diseases, neurodegenerative diseases and pain.
    类似技术:
    公开号 | 公开日 | 专利标题
    US10010536B2|2018-07-03|Method of modulating stress-activated protein kinase system
    JP6023846B2|2016-11-09|Derivatives of 1-phenyl-2-pyridinylalkyl alcohol as phosphodiesterase inhibitors
    USRE47142E1|2018-11-27|Compounds and methods for treating inflammatory and fibrotic disorders
    EP1303490B1|2008-07-09|N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
    US6417185B1|2002-07-09|Inhibitors of glycogen synthase kinase 3
    US20200163937A1|2020-05-28|Pyrazole-amide compounds and pharmaceutical use thereof
    US8273772B2|2012-09-25|Heteroaryl compounds as P2Y1 receptor inhibitors
    JP4800964B2|2011-10-26|Heteroarylindolecarboxamides and analogs thereof for use as glucokinase activators in the treatment of obesity
    AU2003292229B2|2007-05-24|5-substituted-pyrazine or pyridine glucokinase activators
    JP5261176B2|2013-08-14|Voltage-gated sodium channel inhibitor
    KR100519826B1|2005-10-06|Para-amine substituted phenylamide glucokinase activators
    JP5295961B2|2013-09-18|Certain substituted amides, methods of making and using the same
    EP2855489B1|2017-01-04|Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 | inhibitors for treating platelet aggregation
    EP1400518B1|2007-01-17|Heterocyclic compound derivatives and medicines
    US4968697A|1990-11-06|2-substituted adenosine 5&#39;-carboxamides as antihypertensive agents
    TWI304062B|2008-12-11|N-|-sulfonamide derivatives
    CA2467552C|2011-05-24|Nicotin-or isonicotin benzothiazole derivatives
    EP1567112B1|2008-10-15|THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS
    KR100933652B1|2009-12-23|Activator of Peroxysome Proliferative Responsive Receptor δ
    DE69730345T2|2005-09-22|Triarylethane derivatives as pde iv hemmer
    AU775159B2|2004-07-22|Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
    AU2002325316B8|2003-02-17|Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
    US6989451B2|2006-01-24|Heterocyclic compounds and uses thereof
    KR101149954B1|2012-06-01|Sulfonamide compound
    US7612200B2|2009-11-03|Inhibitors of protein kinases
    同族专利:
    公开号 | 公开日
    IL162266D0|2005-11-20|
    MY134892A|2007-12-31|
    AU2002358055B2|2007-09-06|
    TW200306306A|2003-11-16|
    WO2003053441A1|2003-07-03|
    DK1455785T3|2009-06-08|
    NZ533384A|2006-05-26|
    ZA200404566B|2005-08-31|
    DE10238113A1|2003-06-18|
    AR037477A1|2004-11-10|
    TWI333487B|2010-11-21|
    IL162266A|2010-06-30|
    PT1455785E|2009-04-24|
    PL208627B1|2011-05-31|
    AU2002358055B8|2003-07-09|
    HK1078266A1|2010-04-16|
    UA77730C2|2007-01-15|
    UY27571A1|2003-07-31|
    BR0214870A|2004-12-28|
    CA2469586A1|2003-07-03|
    HRP20040618A2|2005-06-30|
    HU0402264A3|2010-03-29|
    AT424202T|2009-03-15|
    PE20030694A1|2003-09-22|
    SV2004001432A|2004-02-24|
    US7109218B2|2006-09-19|
    CY1109063T1|2014-07-02|
    SI1455785T1|2009-08-31|
    AU2002358055A1|2003-07-09|
    MXPA04005624A|2004-12-06|
    EP1455785A1|2004-09-15|
    HRP20040618B1|2013-07-31|
    US20050227972A1|2005-10-13|
    DE50213336D1|2009-04-16|
    ES2321387T3|2009-06-05|
    JP4542778B2|2010-09-15|
    RU2315757C2|2008-01-27|
    RU2315757C9|2008-10-27|
    RU2004121161A|2006-01-10|
    MA26348A1|2004-10-01|
    JP2005516022A|2005-06-02|
    CN100522945C|2009-08-05|
    AR088940A2|2014-07-16|
    US20060217373A1|2006-09-28|
    PL370163A1|2005-05-16|
    KR100958474B1|2010-05-17|
    CO5590927A2|2005-12-30|
    EP1455785B1|2009-03-04|
    HU230059B1|2015-06-29|
    CA2469586C|2011-02-22|
    CN1617721A|2005-05-18|
    HU0402264A2|2005-02-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2001-12-11|Priority to DE10160661
    2001-12-11|Priority to DE10160661.3
    2002-08-21|Priority to DE10238113A
    2002-08-21|Priority to DE10238113.5
    2002-11-28|Application filed by 바이엘 헬스케어 아게
    2002-11-28|Priority to PCT/EP2002/013432
    2004-07-19|Publication of KR20040064736A
    2010-05-17|Application granted
    2010-05-17|Publication of KR100958474B1
    优先权:
    申请号 | 申请日 | 专利标题
    DE10160661|2001-12-11|
    DE10160661.3|2001-12-11|
    DE10238113A|DE10238113A1|2001-12-11|2002-08-21|New 2-substituted methylthio-dicyanopyridine derivatives, useful for treating or preventing e.g. cardiovascular disease and inflammation, are adenosine A1 receptor agonists|
    DE10238113.5|2002-08-21|
    PCT/EP2002/013432|WO2003053441A1|2001-12-11|2002-11-28|Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same|
    [返回顶部]